Peptides aren't simple: what TikTok gets wrong about 'easy' biology

What did @biosignalpeptide1 actually say?

Dr. Adam Bunder introduced a content series called "the peptide pulse" and made two sweeping promises: that peptides are "safe" and "effective," and that they will "transform the way that medicine is actually utilized" globally. He also leaned hard on anecdotal evidence, saying real-life experience "drives the industry forward" whether it is "anecdotal or science based."

To be fair, he framed this as an introductory video, not a clinical deep-dive. He is not prescribing anything here. But blanket claims about safety and effectiveness applied to an entire category of compounds, many of which have wildly different mechanisms, regulatory statuses, and evidence bases, are the kind of statements that deserve real scrutiny before 1,600 viewers walk away thinking peptides are a proven, risk-free category of medicine.

Does the science back this up?

Not uniformly, no. The peptide category is enormous and heterogeneous. Lumping BPC-157, MK-677, and GHK-Cu under one "safe and effective" umbrella is a bit like saying "drugs are safe." It depends entirely on which one, at what dose, in which person, for which condition.

Some peptides have legitimate clinical evidence behind them. GLP-1 receptor agonists are FDA-approved. Thymosin alpha-1 has data in immunomodulation (Tuthill et al., 2002, International Immunopharmacology). BPC-157 shows promising results in rodent models for gut healing and tendon repair, but human randomized controlled trial data is essentially nonexistent as of 2024. TB-500 (thymosin beta-4) has early-phase human trials but nothing close to approval. MK-677 is not a peptide at all, it is a small molecule ghrelin mimetic, and its long-term safety profile in healthy adults is poorly characterized. Framing all of these compounds under a single safety-and-efficacy banner is misleading by omission.

What did they get wrong (or right)?

What he got wrong is the framing. Saying peptides "are safe" as a category claim is not supported by the evidence base. Several peptides used in the optimization space, including CJC-1295 and ipamorelin stacks, lack long-term human safety data entirely. The FDA has taken action against compounded versions of multiple peptides precisely because of safety and purity concerns. In 2023 and 2024, the FDA placed BPC-157 and TB-500 on lists of substances that cannot be compounded under 503A or 503B regulations, citing a lack of adequate safety data.

What he got partially right is the acknowledgment that anecdotal evidence "has to start somewhere." That is true. Patient-reported outcomes have historically preceded formal clinical research. But he uses this framing to equate anecdote with science, which is a logical step too far. Anecdote generates hypotheses. It does not validate them.

What should you actually know?

If you are considering peptide therapy, the regulatory context matters more than any individual creator's enthusiasm. In the United States, many peptides discussed in optimization communities are not FDA-approved for the uses being promoted. Some are research chemicals. Some are available only through compounding pharmacies, and the quality and purity of compounded peptides vary significantly depending on the pharmacy.

A 2021 analysis published in JAMA Internal Medicine found that a substantial proportion of compounded medications tested failed potency or sterility standards. That finding applies broadly to compounding, and peptide compounding is no exception. Patients seeking peptide therapy through telehealth platforms should ask specific questions: Is this peptide FDA-approved for my condition? Is it available through a licensed 503B outsourcing facility? What does the prescribing physician know about contraindications for my specific health history?

The enthusiasm in this video is not inherently wrong. Peptide science is genuinely interesting and moving fast. But "exciting" and "safe and effective" are not the same sentence.